OptimizeRx (NASDAQ:OPRX) Stock Rating Upgraded by Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Thursday.

Several other research firms have also recently commented on OPRX. Stifel Nicolaus increased their price target on shares of OptimizeRx from $8.00 to $12.50 and gave the company a “buy” rating in a research note on Tuesday, May 13th. JMP Securities increased their price target on shares of OptimizeRx from $11.00 to $14.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 13th. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. B. Riley reissued a “buy” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Citigroup reissued an “outperform” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and a consensus price target of $10.38.

OptimizeRx Price Performance

Shares of OptimizeRx stock opened at $11.65 on Thursday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $215.47 million, a price-to-earnings ratio of -8.76 and a beta of 1.28. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $13.19. The firm’s 50-day moving average price is $9.16 and its two-hundred day moving average price is $6.70.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.19. The firm had revenue of $21.93 million for the quarter, compared to analysts’ expectations of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. On average, equities analysts predict that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of OptimizeRx stock in a transaction on Friday, March 14th. The shares were purchased at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the purchase, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently bought and sold shares of OPRX. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx in the fourth quarter worth $25,000. GAMMA Investing LLC acquired a new stake in OptimizeRx in the first quarter worth $33,000. SG Americas Securities LLC acquired a new stake in OptimizeRx in the fourth quarter worth $51,000. Wells Fargo & Company MN raised its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after purchasing an additional 2,797 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in OptimizeRx in the fourth quarter worth $81,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.